Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 in Advanced Renal Cancer
NCT06222125Phase 2Recruiting
- Sponsor
- Huabo Biopharm
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sotiburafusp alfa in clear cell renal cell carcinoma (ccRCC), sponsored by Huabo Biopharm. Started Jan 2023; status: recruiting.
02
Drugs
sotiburafusp alfa
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06222125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222125.